CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Velcade +1 moredrug
Likely dose
Velcade 1.6 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01281917
NCT01281917Phase 2Completed
CompareCT.gov

A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

University of Wisconsin, Madison·interventional·Posted Jan 24, 2011·Updated Dec 13, 2019

In Brief

A Phase 2 clinical trial evaluating Velcade and Temsirolimus for Non-Hodgkins Lymphoma. Completed, enrolled 40 participants across 18 sites.

Detailed Summary

The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkins Lymphoma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc., Pfizer, National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 24, 2011
Enrollment StartFeb 1, 2011
Primary CompletionOct 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.4 years ago

Interventions

Velcadedrug

Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)

Temsirolimusdrug

Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)